The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy;Papel da ectonucleotídeo pirofosfatase/fosfodiesterase 1 (enpp1) na nefropatia diabética

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 55, Issue 9, 2011, Pages 677-685

  Sortica, Denise Alves ^a,b   Crispim, Daisy ^a,b   Zaffari, Guilherme Pozueco ^a,b   Friedman, Rogério ^a,b   Canani, Luis Henrique ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Chronic renal disease; Diabetes mellitus; Diabetic nephropathy; DNA polymorphisms; ENPP1; Insulin resistance

Indexed keywords

ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; INORGANIC PYROPHOSPHATASE; PHOSPHODIESTERASE;

DIABETIC NEPHROPATHY; ENZYMOLOGY; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; PHOSPHORIC DIESTER HYDROLASES; POLYMORPHISM, GENETIC; PYROPHOSPHATASES;

EID: 84855843095     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302011000900002     Document Type: Review

References (63)

1. American Diabetes Association. Diagnosis and classifcation of diabetes mellitus. Diabetes Care. 2009;32(1):62.
2. Gross JL, de Azevedo MJ, Silveiro S P, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76.
3. Carpena M P, Rados DV, Sortica DA, Souza BM, Reis A F, Canani LH, et al. Genetics of diabetic nephropathy. Arq Bras Endocrinol Metabol. 2010;54(3):253-61.
4. Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J. 2004;80(949):624-33.
5. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate suffcient? Diabetes. 2000;49(9):1399-408.
6. Kramer CK, Leitao CB, Pinto LC, Silveiro S P, Gross JL, Canani LH. Clinical and laboratory profle of patients with type 2 diabetes with low glomerular fltration rate and normoalbuminuria. Diabetes Care. 2007;30(8):1998-2000.
7. Bloomgarden Z T. Diabetic nephropathy. Diabetes Care. 2008;31(4):823-7.
8. Bruno RM, Gross JL. Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. J Diabetes Complications. 2000;14(5):266-71.
9. Molitch ME, DeFronzo RA, Franz MJ, Keane W F, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care. 2003;26 Suppl 1:S94-8.
10. Grupe A, Alleman J, Goldfne ID, Sadick M, Stewart TA. Inhibition of insulin receptor phosphorylation by PC-1 is not mediated by the hydrolysis of adenosine triphosphate or the generation of adenosine. J Biol Chem. 1995;270(38):22085-8.
11. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 2003;26(8):2392-9.
12. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-32.
13. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25(6):496-501.
14. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48(4):909-13.
15. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999;55(4):1582-96.
16. Krolewski AS, Warram JH, Rand LI, Christlieb AR, Busick EJ, Kahn CR. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-yr follow-up study. Diabetes Care. 1986;9(5):443-52.
17. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520-6.
18. Canani LH, Gerchman F, Gross JL. Increased familial history of arterial hypertension, coronary heart disease, and renal disease in Brazilian type 2 diabetic patients with diabetic nephropathy. Diabetes Care. 1998;21(9):1545-50.
19. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 1998;15(5):418-26.
20. Conway BR, Savage DA, Maxwell A P. Identifying genes for diabetic nephropathy--current diffculties and future directions. Ne-phrol Dial Transplant. 2006;21(11):3012-7.
21. Martini S, Eichinger F, Nair V, Kretzler M. Defning human diabetic nephropathy on the molecular level: integration of transcriptomic profles with biological knowledge. Rev Endocr Metab Disord. 2008;9(4):267-74.
22. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6):1306-16.
23. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucle-otide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol. 2000;35(6):393-432.
24. Goldfne ID, Maddux BA, Youngren J F, Reaven G, Accili D, Tris-chitta V, et al. The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev. 2008;29(1):62-75.
25. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature. 1995;373(6513):448-51.
26. Maddux BA, Goldfne ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes. 2000;49(1):13-9.
27. Frittitta L, Youngren J F, Sbraccia P, D'Adamo M, Buongiorno A, et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia. 1997;40(3):282-9.
28. Frittitta L, Youngren J, Vigneri R, Maddux BA, Trischitta V, Goldfne ID. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia. 1996;39(10):1190-5.
29. Kumakura S, Maddux BA, Sung CK. Overexpression of membrane glycoprotein PC-1 can infuence insulin action at a post-receptor site. J Cell Biochem. 1998;68(3):366-77.
30. Youngren J F, Maddux BA, Sasson S, Sbraccia P, Tapscott EB, Swanson MS, et al. Skeletal muscle content of membrane glyco-protein PC-1 in obesity. Relationship to muscle glucose transport. Diabetes. 1996;45(10):1324-8.
31. Frittitta L, Spampinato D, Solini A, Nosadini R, Goldfne ID, Vigneri R, et al. Elevated PC-1 content in cultured skin fbroblasts correlates with decreased in vivo and in vitro insulin action in nondiabe-tic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes. 1998;47(7):1095-100.
32. Maddux BA, Chang YN, Accili D, McGuinness O P, Youngren J F, Goldfne ID. Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab. 2006;290(4):E746-9.
33. Zhou HH, Chin CN, Wu M, Ni W, Quan S, Liu F, et al. Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. Eur J Pharmacol. 2009;616(1-3):346-52.
34. Belfore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigne-ri P, et al. Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol. 1996;10(11):1318-26.
35. Costanzo BV, Trischitta V, Di Paola R, Spampinato D, Pizzuti A, Vig-neri R, et al. The Q allele variant (GLN121) of membrane glyco-protein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes. 2001;50(4):831-6.
36. Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfne ID, Bozzali M, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999;48(9):1881-4.
37. Buckley M F, Loveland KA, McKinstry WJ, Garson OM, Goding JW. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem. 1990;265(29):17506-11.
38. Frittitta L, Sbraccia P, Costanzo BV, Tassi V, D'Adamo M, Spam-pinato D, et al. High insulin levels do not infuence PC-1 gene expression and protein content in human muscle tissue and he-patoma cells. Diabetes Metab Res Rev. 2000;16(1):26-32.
39. Menzaghi C, Di Paola R, Baj G, Funaro A, Arnulfo A, Ercolino T, et al. Insulin modulates PC-1 processing and recruitment in cultured human cells. Am J Physiol Endocrinol Metab. 2003;284(3):E514-20.
40. Gu H F, Almgren P, Lindholm E, Frittitta L, Pizzuti A, Trischitta V, et al. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes. 2000;49(9):1601-3.
41. Abate N, Chandalia M. The impact of ethnicity on type 2 diabetes. J Diabetes Complications. 2003;17(1):39-58.
42. Frittitta L, Baratta R, Spampinato D, Di Paola R, Pizzuti A, Vigneri R, et al. The Q121 PC-1 variant and obesity have additive and independent effects in causing insulin resistance. J Clin Endocrinol Metab. 2001;86(12):5888-91.
43. Kubaszek A, Pihlajamaki J, Karhapaa P, Vauhkonen I, Laakso M. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care. 2003;26(2):464-7.
44. Rasmussen SK, Urhammer SA, Pizzuti A, Echwald SM, Ekstrom C T, Hansen L, et al. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes. 2000;49(9):1608-11.
45. Abate N, Chandalia M, Di Paola R, Foster DW, Grundy SM, Tris-chitta V. Mechanisms of disease: ectonucleotide pyrophospha-tase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. Nat Clin Pract Endocrinol Metab. 2006;2(12):694-701.
46. Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, San-deep S, et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes. 2005;54(4):1207-13.
47. Bacci S, Ludovico O, Prudente S, Zhang YY, Di Paola R, Mangia-cotti D, et al. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. Diabetes. 2005;54(10):3021-5.
48. Grarup N, Urhammer SA, Ek J, Albrechtsen A, Glumer C, Bor-ch-Johnsen K, et al. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia. 2006;49(9):2097-104.
49. De Cosmo S, Argiolas A, Miscio G, Thomas S, Piras G P, Trevisan R, et al. A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria. Diabetes. 2000;49(3):521-4.
50. Canani LH, Ng D P, Smiles A, Rogus JJ, Warram JH, Krolewski AS. Polymorphism in ecto-nucleotide pyrophosphatase/phos-phodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes. 2002;51(4):1188-93.
51. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropa-thy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009;24(11):3360-6.
52. De Cosmo S, Minenna A, Zhang YY, Thompson R, Miscio G, Vedo-vato M, et al. Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes. Am J Kidney Dis. 2009;53(2):273-80.
53. De Cosmo S, Trevisan R, Dalla Vestra M, Vedovato M, Argiolas A, Solini A, et al. PC-1 amino acid variant Q121 is associated with a lower glomerular fltration rate in type 2 diabetic patients with abnormal albumin excretion rates. Diabetes Care. 2003;26(10):2898-902.
54. Leitao CB, Nabinger GB, Krahe AL, Bolson PB, Gerchman F, Friedman R, et al. The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications. Braz J Med Biol Res. 2008;41(3):229-34.
55. Keene KL, Mychaleckyj JC, Smith SG, Leak TS, Perlegas PS, Lan-gefeld CD, et al. Association of the distal region of the ectonu-cleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for ne-phropathy. Diabetes. 2008;57(4):1057-62.
56. de Azevedo MJ, Dalmaz CA, Caramori ML, Pecis M, Esteves J F, Maia AL, et al. ACE and PC-1 gene polymorphisms in normoal-buminuric Type 1 diabetic patients: a 10-year prospective study. J Diabetes Complications. 2002;16(4):255-62.
57. Jacobsen P, Grarup N, Tarnow L, Parving HH, Pedersen O. PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. Nephrol Dial Transplant. 2002;17(8):1408-12.
58. Frittitta L, Ercolino T, Bozzali M, Argiolas A, Graci S, Santagati MG, et al. A cluster of three single nucleotide polymorphisms in the 3'-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes. 2001;50(8):1952-5.
59. Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications. 2000;14(3):154-74.
60. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86(2):713-8.
61. Meyre D, Bouatia-Naji N, Tounian A, Samson C, Lecoeur C, Vatin V, et al. Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet. 2005;37(8):863-7.
62. Bochenski J, Placha G, Wanic K, Malecki M, Sieradzki J, Warram JH, et al. New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals. Diabetes. 2006;55(9):2626-30.
63. Santoro N, Cirillo G, Lepore MG, Palma A, Amato A, Savarese P, et al. Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity. J Clin Endocrinol Metab. 2009;94(1):300-5.